Evogene Stock Analysis

Evogene Stock Analysis Notes

The company recorded a loss per share of 2.51. Evogene had not issued any dividends in recent years. The entity had 1:10 split on the 25th of July 2024. Evogene Ltd., together with its subsidiaries, operates as a computational biology company. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel. Evogene operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 133 people. To learn more about Evogene call Ofer CPA at 972 8 931 1900 or check out https://www.evogene.com.

Evogene Investment Alerts

Evogene Upcoming and Recent Events

Evogene Largest EPS Surprises

View All Earnings Estimates

Evogene Thematic Classifications

Evogene Stock Institutional Investors

Note, although Evogene's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Evogene Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 12.35 M.

Evogene Profitablity

The company has Profit Margin (PM) of (2.25) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.69) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.69.

Management Efficiency

Evogene has return on total asset (ROA) of (0.351) % which means that it has lost $0.351 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9105) %, meaning that it created substantial loss on money invested by shareholders. Evogene's management efficiency ratios could be used to measure how well Evogene manages its routine affairs as well as how well it operates its assets and liabilities. As of the 21st of July 2025, Return On Equity is likely to grow to 11.93, while Return On Tangible Assets are likely to drop (0.63). At this time, Evogene's Total Assets are very stable compared to the past year. As of the 21st of July 2025, Other Current Assets is likely to grow to about 3.1 M, while Other Assets are likely to drop 1.09.

Technical Drivers

As of the 21st of July, Evogene shows the Downside Deviation of 6.66, mean deviation of 5.6, and Coefficient Of Variation of 1379.02. Evogene technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.

Evogene Price Movement Analysis

Evogene Outstanding Bonds

Evogene Predictive Daily Indicators

Evogene Forecast Models

Evogene's time-series forecasting models are one of many Evogene's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Evogene's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Evogene prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Evogene shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Evogene. By using and applying Evogene Stock analysis, traders can create a robust methodology for identifying Evogene entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Evogene analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Evogene analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Evogene stock analysis indicators help investors evaluate how Evogene stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Evogene shares will generate the highest return on investment. By understating and applying Evogene stock analysis, traders can identify Evogene position entry and exit signals to maximize returns.

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evogene. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Evogene Stock, please use our How to Invest in Evogene guide.You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Evogene. If investors know Evogene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Evogene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Evogene is measured differently than its book value, which is the value of Evogene that is recorded on the company's balance sheet. Investors also form their own opinion of Evogene's value that differs from its market value or its book value, called intrinsic value, which is Evogene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Evogene's market value can be influenced by many factors that don't directly affect Evogene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Evogene's value and its price as these two are different measures arrived at by different means. Investors typically determine if Evogene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Evogene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.